leptin and Autistic-Disorder

leptin has been researched along with Autistic-Disorder* in 8 studies

Trials

1 trial(s) available for leptin and Autistic-Disorder

ArticleYear
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
    The American journal of psychiatry, 2004, Volume: 161, Issue:6

    The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change.. Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months. Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site, gender, age, and risperidone dose.. Age- and gender-standardized weight increased after 6 months of treatment (gross: mean=5.6 kg [SD=3.9]; standardized: mean=0.6 z [SD=0.5]) and was positively correlated with weight gained after 1 month. Change in leptin levels after 2 months of treatment (mean=-0.3 ng/ml, SD=6.2) (N=48) did not predict final weight gain.. Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time. Serum leptin change does not reliably predict risperidone-associated weight gain.

    Topics: Adolescent; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Body Weight; Child; Child, Preschool; Female; Humans; Leptin; Male; Prospective Studies; Risperidone; Weight Gain

2004

Other Studies

7 other study(ies) available for leptin and Autistic-Disorder

ArticleYear
Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders.
    Clinical biochemistry, 2017, Volume: 50, Issue:12

    To evaluate the influence of dose and duration of risperidone treatment on cardiovascular and diabetes risk biomarkers in children and adolescents with autistic spectrum disorders (ASDs).. In this cross-sectional analysis, a total of 168 ASDs patients (89% male) treated with a risperidone-based regimen for ≥12months were included. Blood samples were analyzed for glucose and lipid metabolic markers, adiponectin, leptin, prolactin, cortisol and high sensitive C-reactive protein.. The mean concentrations of glucose, insulin, prolactin and leptin and HOMA-IR significantly rose with risperidone dosage (all P<0.025), but those of adiponectin and cortisol did not. Using regression analysis, insulin, leptin, prolactin and glucose concentrations and HOMA-IR show significant association with dosage. None of the markers except adiponectin showed dependence on duration of treatment. However, insulin and leptin concentrations and HOMA-IR clearly increased with increasing both dosage and duration. Dosage and duration of treatment had minimal effect on standard lipid profile and lipoprotein subclasses.. Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms. Metabolic adverse effects, especially development of type 2 diabetes mellitus should be closely monitored, particularly in individuals receiving high doses and/or long-term risperidone treatment.

    Topics: Adiponectin; Adolescent; Antipsychotic Agents; Autistic Disorder; Blood Glucose; C-Reactive Protein; Child; Child, Preschool; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydrocortisone; Insulin; Insulin Resistance; Leptin; Male; Monitoring, Physiologic; Prolactin; Risperidone

2017
1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: implication for behavioral influences of vitamin D.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015, Volume: 29, Issue:9

    To investigate vitamin D-related control of brain-expressed genes, candidate vitamin D responsive elements (VDREs) at -7/-10 kb in human tryptophan hydroxylase (TPH)2 were probed. Both VDREs bound the vitamin D receptor (VDR)-retinoid X receptor (RXR) complex and drove reporter gene transcription in response to 1,25-dihydroxyvitamin D3 (1,25D). Brain TPH2 mRNA, encoding the rate-limiting enzyme in serotonin synthesis, was induced 2.2-fold by 10 nM 1,25D in human U87 glioblastoma cells and 47.8-fold in rat serotonergic RN46A-B14 cells. 1,25D regulation of leptin (Lep), encoding a serotoninlike satiety factor, was also examined. In mouse adipocytes, 1,25D repressed leptin mRNA levels by at least 84%, whereas 1,25D induced leptin mRNA 15.1-fold in human glioblastoma cells. Chromatin immunoprecipitation sequencing analysis of the mouse Lep gene in response to 1,25D revealed a cluster of regulatory sites (cis-regulatory module; CRM) at -28 kb that 1,25D-dependently docked VDR, RXR, C/EBPβ, and RUNX2. This CRM harbored 3 VDREs and single C/EBPβ and RUNX2 sites. Therefore, the expression of human TPH2 and mouse Lep are governed by 1,25D, potentially via respective VDREs located at -7/-10 kb and -28 kb. These results imply that vitamin D affects brain serotonin concentrations, which may be relevant to psychiatric disorders, such as autism, and may control leptin levels and affect eating behavior.

    Topics: 3T3-L1 Cells; Animals; Autistic Disorder; Behavior, Animal; Calcitriol; Cell Line, Tumor; Feeding Behavior; Gene Expression Regulation; HEK293 Cells; Humans; Leptin; Mice; Response Elements; RNA, Messenger; Tryptophan Hydroxylase

2015
Predicting infant neurodevelopmental outcomes using the placenta?
    Trends in molecular medicine, 2014, Volume: 20, Issue:6

    Identifying those infants most at risk for poor neurodevelopmental outcomes is crucial to allow for targeted surveillance or preventative interventions to be instigated from birth. One intriguing possibility is to use the molecular characteristics of the placenta at birth as a 'molecular barometer' of the in utero experience to predict future infant neurodevelopmental outcomes. Here we highlight the recent advances in the field and discuss the possibilities for an integrated approach across the '-omics' categories.

    Topics: Autistic Disorder; Child Development; Developmental Disabilities; Female; Humans; Infant; Infant, Small for Gestational Age; Leptin; Methylation; Placenta; Pregnancy

2014
Altered ghrelin levels in boys with autism: a novel finding associated with hormonal dysregulation.
    Scientific reports, 2014, Sep-26, Volume: 4

    Autism is a neurodevelopmental disorder with unclear pathogenesis. Many clinical observations and hormone studies have suggested the involvement of the neuroprotective hormone ghrelin in autism. The current study aimed to investigate the potential role of ghrelin in autism and to elucidate the associated hormonal dysregulation. This case-control study investigated acyl ghrelin (AG), des-acyl ghrelin (DG), total testosterone (TT), free testosterone (FT), leptin and growth hormone (GH) levels in 31 male children with autism and 28 healthy age and sex-matched controls. Hormone levels were measured in the blood using enzyme-linked immunosorbent assay and chemiluminescence immunoassay kits. AG, DG and GH levels were significantly lower in the autism group than in the control group (p ≤ 0.001, p ≤ 0.005 and p ≤ 0.05, respectively). However, TT, FT and leptin levels were significantly higher in the autism group than in the control group (p ≤ 0.05, p ≤ 0.001 and p ≤ 0.01, respectively). Our results for the first time demonstrate low AG and DG levels in autistic children. Considering the capacity of ghrelin to affect neuroinflammatory and apoptotic processes that are linked to autism, this study suggests a potential role for the hormone ghrelin in the pathogenesis of autism.

    Topics: Autistic Disorder; Case-Control Studies; Child; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Ghrelin; Humans; Leptin; Male; Testosterone

2014
Leptin as a new approach for treatment for autism and epilepsy, a hypothesis with clinical implications.
    Brain & development, 2011, Volume: 33, Issue:1

    Topics: Animals; Autistic Disorder; Diet, Ketogenic; Disease Models, Animal; Epilepsy; Humans; Leptin; Receptors, Leptin; Rett Syndrome

2011
Variations of plasma leptin and adiponectin levels in autistic patients.
    Neuroscience letters, 2010, Jul-19, Volume: 479, Issue:1

    Autism is a neurodevelopmental disorder with pathogenesis not completely understood. Although a genetic origin has been recognized, it has been hypothesized a role for environmental factors, immune dysfunctions, and alterations of neurotransmitter systems. In young autistic patients we investigated plasma leptin and adiponectin levels over a year period. Thirty-five patients, mean age at the basal time 14.1+/-5.4 years, were enrolled. Controls were 35 healthy subjects, sex and age matched. Blood samples were withdrawn in the morning at the baseline and 1 year after. In patients leptin concentrations significantly increased, while adiponectin did not significantly change. Leptin values in patients were significantly higher than those found in controls at each time; adiponectin values did not differ at each time between patients and controls. Since patients were not obese, we could hypothesize that leptin might participate to clinical manifestations other than weight balance. The role of adiponectin in autism is still debatable.

    Topics: Adiponectin; Adolescent; Analysis of Variance; Antimanic Agents; Autistic Disorder; Body Mass Index; Carbamazepine; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leptin; Male; Puberty; Sex Factors; Time Factors

2010
Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype?
    Journal of autism and developmental disorders, 2008, Volume: 38, Issue:1

    There is evidence of both immune dysregulation and autoimmune phenomena in children with autism spectrum disorders (ASD). We examined the hormone/cytokine leptin in 70 children diagnosed with autism (including 37 with regression) compared with 99 age-matched controls including 50 typically developing (TD) controls, 26 siblings without autism, and 23 children with developmental disabilities (DD). Children with autism had significantly higher plasma leptin levels compared with TD controls (p<.006). When further sub-classified into regression or early onset autism, children with early onset autism had significantly higher plasma leptin levels compared with children with regressive autism (p<.042), TD controls (p<.0015), and DD controls (p<.004). We demonstrated an increase in leptin levels in autism, a finding driven by the early onset group.

    Topics: Adolescent; Age of Onset; Autistic Disorder; Child; Child, Preschool; Female; Humans; Leptin; Male; Phenotype

2008